Dr. Sinh presented Gene Solutions’s real-world data from over 600 Southeast Asian cancer patients, demonstrating the clinical utility of tumor-informed ctDNA through the K-TRACK test. The assay achieved high sensitivity (75.0%–100.0%) and specificity (87.5%–97.9%) in predicting recurrence, with detection occurring up to 19 months before imaging in colorectal cancer. It also revealed resistance mutations in lung and breast cancers. Through case-based insights, Dr. Sinh underscored the value of longitudinal MRD tracking in guiding adjuvant therapy, personalizing surveillance, and outperforming conventional markers like CEA.
